Opioid Use Disorder
Conditions
Keywords
mood, cravings, retention
Brief summary
This study aims to evaluate feasibility of a virtual reality software device and measure the effects of the intervention on OUD patient mood, tension and cravings, as well as the effect of treatment on patient retention to their inpatient detox protocol.
Detailed description
The primary objective of this study is to evaluate the feasibility and preliminary effectiveness of a novel virtual reality (VR) based intervention; 3D Therapy Thrive (3DTT). Inpatient detoxification can improve outcomes for individuals with opioid use disorder (OUD), however patients often leave treatment early due to mood, tension, and cravings associated with opioid withdrawal. Subjects were recruited from a community inpatient detoxification program and received up to two sessions of 3DTT. The patients completed surveys to assess their mood, distress, cravings, and overall satisfaction with the experience. Retention was measured by protocol completion as reported by clinic staff, independent of the study. A group of patients with OUD consecutively admitted to the program comprised a comparison treatment-as-usual (TAU) group.
Interventions
DEVICE3D Therapy Thrive
A novel virtual reality software intervention that utilizes elements of Cognitive Behavioral Therapy to improve outcomes for inpatients with OUD.
Sponsors
3D Therapy, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
SINGLE (Subject)
Masking description
Subjects were blinded to study condition.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1.18 years or older 2\. Current diagnosis of opioid use disorder 3\. Current inpatient in detox ATS unit 4\. Fluent in English
Exclusion criteria
1. Active suicidality 2. History of seizures 3. History of psychosis 4. Severe visual impairment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Retention in Treatment | At departure from facility, through study completion, an average of 10 days | Medical record indicating whether patient completed detox protocol (i.e., completed, left against medical advice, administratively discharged, or moved to higher level of care) |
| Feasibility and Tolerability of 3DTT | Immediately after each treatment | Feasibility and tolerability of 3DTT was measured by the Side Effects Questionnaire. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mood | Before and after each treatment, approximately every other day for up to 5 days | Depressive symptoms as measured by the AB-POMS depression scale (0-4, not at all to extremely) |
| Anxiety | Before and after each treatment, approximately every other day for up to 5 days | Anxiety symptoms as measured by the AB-POMS scale (0-4, not at all to extremely) |
| Cravings | Before and after each treatment, approximately every other day for up to 5 days | Opioid cravings as measured by the Visual Analog Scale (1-10, with higher scores indicating greater cravings.) |
Countries
United States
Outcome results
None listed